Safety and Immunogenicity of DTaP-IPV/Hib Pentavalent Vaccine in Chinese 2-month-old Infants

ConditionsPertussis Diphtheria Tetanus Haemophilus Influenzae Type B Infection Polio

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age19-22

SponsorJiangsu Province Centers for Disease Control and Prevention

About this trial

The main purpose of this study is to evaluate immune persistence at 30 and 36 Months of Age and Pertussis Breakthrough Infections between 19 and 36 Months of Age following two regiments of DTaP-IPV/Hib Pentavalent Vaccine in Healthy 2-Month-Old Infants and Children in China.

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

Different immunization regiments with DTaP-IPV/Hib Pentavalent Vaccine

Treatment groups

785 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Jiangsu Province Centers for Disease Control and Prevention

Lead sponsor

Source ClinicalTrials.gov